<p>CUTIA (02487.HK) announced its full-year results for the year ending last December, with revenue of RMB 336 million, an increase of 20.2% year-on-year. Losses narrowed to RMB 340 million, compared to a loss of RMB 434 million in the same period of 2024; loss per share was RMB 1.03. No dividend was declared</p>

159992

512290

588130

<p>CUTIA announced its full-year results for the year ended December last year, with a revenue of RMB 336 million, an increase of 20.2% year-on-year. The loss narrowed to RMB 340 million, compared to a loss of RMB 434 million in the same period of 2024; the loss per share was RMB 1.03. No dividend was declared</p>

AASTOCKS

Yinhua CSI Innovative Drugs Industry ETF

Guotai CSI Bio-medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

CUTIA-B

Minsheng Royal CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

"Performance" CUTIA's annual loss narrowed to 340 million RMB, no dividend declared